Immune checkpoint inhibitors have significantly transformed the treatment paradigm for
metastatic renal cell carcinoma (RCC), offering prolonged overall survival and achieving …

A shift toward a T cell exhaustion phenotype is associated with the upregulation of
expression of programmed cell death protein 1 (PD-1) on T lymphocytes in patients with …

Introduction Immune checkpoint blockade (ICB) improved clinical outcomes in renal and
bladder cancer patients, but the response rates remain limited especially in metastatic …

Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor
survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major …

Background Clear cell carcinoma of the kidney is a common urological malignancy
characterized by poor patient prognosis and treatment outcomes. Modulation of …

Les progrès engendrés par l'immunothérapie dans le cancer du rein ont été majeurs lors de
la dernière décennie. Les combinaisons d'immunothérapie (double immunothérapie ou …

Special populations in metastatic renal cell carcinoma : Current Opinion in Oncology Special
populations in metastatic renal cell carcinoma : Current Opinion in Oncology Log in or Register …

Immune checkpoint inhibitors (ICI)-based combinations have become the standard first-line
treatment for advanced clear cell renal cell carcinoma (ccRCC). Despite significant …

Background: Identifying breast cancer markers with superior sensitivity, cost-effectiveness,
and practicality is imperative. Circulating immune cells and plasma cytokines hold promise …

Background and objectives: Immunotherapies targeting PD-1 and CTLA-4 are key
components of the treatment of metastatic clear cell renal cell carcinoma (mccRCC) …